NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Lista de Ações・Roche Holding AG

Roche Holding AG

Fechado

SetorSaúde

325.6 0.74

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

325.4

Máximo

326.6

Indicadores-chave
By Trading Economics
Rendimento	1.8B 5.5B
Vendas	15B 31B
P/E Médio do Setor	20.461 67.147
Rendimento de Dividendos	2.97
Margem de lucro	17.892
Funcionários	103,249
EBITDA	5.1B 12B

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	2.97% 2.36%

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-28B 261B
Abertura anterior	324.86
Fecho anterior	325.6

Sentimento de Notícias

By Acuity

14%

86%

24 / 347 Ranking em Healthcare

Roche Holding AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 07:46 UTC

Ganhos

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 de abr. de 2026, 05:40 UTC

Ganhos

Roche Backs Full-Year View as Quarterly Sales Rise

9 de mar. de 2026, 16:43 UTC

Grandes Movimentos do Mercado

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 de mar. de 2026, 15:44 UTC

Grandes Movimentos do Mercado

Correction to Roche Shares Article

9 de mar. de 2026, 09:51 UTC

Grandes Movimentos do Mercado

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 de mar. de 2026, 09:24 UTC

Grandes Movimentos do Mercado

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 de jan. de 2026, 10:07 UTC

Ganhos

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 de jan. de 2026, 07:07 UTC

Ganhos

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

27 de abr. de 2026, 09:54 UTC

Conversa de Mercado

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 de abr. de 2026, 08:10 UTC

Conversa de Mercado

Ganhos

Roche Reports In Line Sales Figures -- Market Talk

23 de abr. de 2026, 05:04 UTC

Ganhos

Roche Backs 2026 View

23 de abr. de 2026, 05:04 UTC

Ganhos

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 de abr. de 2026, 05:03 UTC

Ganhos

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 de abr. de 2026, 05:02 UTC

Ganhos

Roche 1Q Group Sales Up 6% at Constant Currency

23 de abr. de 2026, 05:02 UTC

Ganhos

Analysts Saw Roche 1Q Sales at CHF14.73B

23 de abr. de 2026, 05:01 UTC

Ganhos

Roche 1Q Sales CHF14.72B

10 de abr. de 2026, 11:28 UTC

Conversa de Mercado

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 de abr. de 2026, 11:17 UTC

Conversa de Mercado

Roche to Face Significant Currency Headwinds -- Market Talk

11 de mar. de 2026, 10:57 UTC

Conversa de Mercado

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 de mar. de 2026, 09:43 UTC

Ações em Alta

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 de mar. de 2026, 07:22 UTC

Conversa de Mercado

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 de mar. de 2026, 07:22 UTC

Conversa de Mercado

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 de mar. de 2026, 14:21 UTC

Conversa de Mercado

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 de jan. de 2026, 11:40 UTC

Conversa de Mercado

Ganhos

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 de jan. de 2026, 06:05 UTC

Ganhos

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 de jan. de 2026, 06:04 UTC

Ganhos

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 de jan. de 2026, 06:03 UTC

Ganhos

Roche Issues 2026 View

29 de jan. de 2026, 06:02 UTC

Ganhos

Analysts Saw 2025 Core EPS at CHF19.70

29 de jan. de 2026, 06:02 UTC

Ganhos

Roche: 2025 Core EPS CHF19.46

29 de jan. de 2026, 06:01 UTC

Ganhos

Analysts Had Seen 2025 Sales At CHF61.47B

Comparação entre Pares

Variação de preço

Roche Holding AG Previsão

Consenso de Avaliação

By TipRanks

0 ratings

Comprar

Manter

Vender

Com base em 0 analistas que deram avaliações de ações para Roche Holding AG - Dist nos últimos 3 meses.

Sentimento

By Acuity

24 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.